iProtics is a groundbreaking company dedicated to revolutionizing the treatment of cancer and auto-immune disorders.

With a deep understanding of proteasomes, crucial protein-regulating complexes, iProtics aims to develop selective immunoproteasome inhibitors that target disease-causing cells while preserving the integrity of healthy tissues. Unlike current clinical drugs that indiscriminately affect both cancerous and somatic cells, iProtics’ innovative approach offers a paradigm shift in therapy. Founded by a skilled team encompassing expertise in design, synthesis, drug development, and business strategies, iProtics builds upon the remarkable discoveries made by the esteemed Overkleeft group at Leiden University.